Q3 EPS Estimates for Vor Biopharma Lowered by HC Wainwright

Key Points

• HC Wainwright has reduced its Q3 2025 earnings per share (EPS) estimate for Vor Biopharma to ($0.22), down from a prior forecast of ($0.18), while maintaining a "Buy" rating with a price target of $3.00.
• Multiple brokerages have downgraded their ratings on Vor Biopharma, with several moving from "strong-buy" to "hold," reflecting a cautious outlook among analysts.
• Vor Biopharma's shares have shown significant movement, with a recent trading price of $2.14, indicating an 8.1% increase, amidst a broad presence of institutional investors owning 97.29% of the stock.

Vor Biopharma Inc. (NYSE:VOR - Free Report) - Investment analysts at HC Wainwright lowered their Q3 2025 EPS estimates for shares of Vor Biopharma in a research note issued on Thursday, August 14th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.22) per share for the quarter, down from their previous forecast of ($0.18). HC Wainwright currently has a "Buy" rating and a $3.00 target price on the stock. The consensus estimate for Vor Biopharma's current full-year earnings is ($1.42) per share. HC Wainwright also issued estimates for Vor Biopharma's Q4 2025 earnings at ($0.20) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.78) EPS and FY2027 earnings at ($0.73) EPS.

A number of other equities research analysts have also weighed in on the stock. Baird R W lowered shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Citizens Jmp lowered shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 9th. JMP Securities reissued a "market perform" rating and set a $6.00 price objective on shares of Vor Biopharma in a report on Friday, May 9th. Jones Trading downgraded shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Finally, Wedbush reissued an "outperform" rating on shares of Vor Biopharma in a report on Thursday, June 26th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $6.07.

Vor Biopharma Stock Up 0.5%

VOR stock traded up $0.01 during midday trading on Monday, hitting $2.05. The company's stock had a trading volume of 1,903,977 shares, compared to its average volume of 7,965,143. Vor Biopharma has a 52-week low of $0.13 and a 52-week high of $3.29. The firm has a market capitalization of $259.70 million, a P/E ratio of -1.24 and a beta of 2.06. The firm has a 50-day simple moving average of $1.66 and a 200-day simple moving average of $1.05.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new position in Vor Biopharma during the 2nd quarter valued at $66,000. Goldman Sachs Group Inc. raised its holdings in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after purchasing an additional 58,247 shares during the period. Jane Street Group LLC acquired a new stake in shares of Vor Biopharma during the first quarter worth $140,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Vor Biopharma during the first quarter worth $100,000. Finally, Money Concepts Capital Corp raised its holdings in shares of Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after purchasing an additional 26,535 shares during the period. 97.29% of the stock is currently owned by institutional investors.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.